Calliditas Therapeutics AB logo

CALT

Calliditas Therapeutics AB

$22.8

Earnings Summary

Q4 FY2022-2023Q3 FY2022-2023Q2 FY2022-2023Q1 FY2022-2023Q4 FY2021-2022Q3 FY2021-2022Q2 FY2021-2022Q1 FY2021-2022Q4 FY2020-2021Q3 FY2020-2021Q2 FY2020-2021Q1 FY2020-2021Q4 FY2019-2020Q3 FY2019-2020Q2 FY2019-2020Q1 FY2019-2020Q4 FY2018-2019Q3 FY2018-2019Q2 FY2018-2019Q1 FY2018-2019
Net Profits
$-18.18Mn

Highlights

Net Profits:

Calliditas Therapeutics AB’s net profit fell -12.87% since last year same period to $-18.18Mn in the Q2 2018. On a quarterly growth basis, Calliditas Therapeutics AB has generated 52.44% jump in its net profits since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Calliditas Therapeutics AB post its latest quarter earnings

EPS Estimate Current Quarter
0.27
EPS Estimate Current Year
0.27

Highlights

EPS Estimate Current Quarter:

Calliditas Therapeutics AB’s earning per share (EPS) estimates for the current quarter stand at 0.27 - a 178.77% jump from last quarter’s estimates.

EPS Estimate Current Year:

Calliditas Therapeutics AB’s earning per share (EPS) estimates for the current year stand at 0.27.

Key Ratios

Key ratios of the Calliditas Therapeutics AB post its Q1 2023 earnings

Earning Per Share (EPS)
0

Highlights

Earning Per Share (EPS):

Calliditas Therapeutics AB’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q1 2023. This indicates that the Calliditas Therapeutics AB has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Earnings Calendar

202320222021202020192018
Earnings DateEstimated EPSReported EPSSurprise %
2020-12-31
-0.45
-0.79
-75.56%
2020-03-31
0
-0.34
-Inf%
2020-09-30
-0.26
-0.62
-138.46%
2020-06-30
-0.4
-0.31
22.5%

Company Information

Calliditas is a clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.

Organisation
Calliditas Therapeutics AB
Headquarters
Kungsbron 1, D5, Stockholm, Sweden, 111 22
Employees
102
Industry
Health Technology
CEO
Renee J. Aguiar-Lucander